Source:http://linkedlifedata.com/resource/pubmed/id/16343238
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2005-12-13
|
| pubmed:abstractText |
The introduction of paclitaxel/platinum combination chemotherapy and (interval) debulking surgery has significantly improved the prognosis of patients with ovarian cancer. Yet, many patients die of drug-resistant disease. Second-line chemotherapy may result in prolonged secondary remissions with alleviation of symptoms and improvement of quality of life. The response to second-line chemotherapy is strongly related to platinum sensitivity. More than 60% of platinum-sensitive patients respond to a re-challenge with platinum-containing chemotherapy. In platinum-resistant patients, on the contrary, the response rate to a re-challenge with 3-weekly platinum or any nonplatinum chemotherapy is less than 20%. The response to dose-dense weekly platinum-based regimens ranged from 48% to 64% in platinum-resistant patients. Moreover, the majority of the patients responded within 8 weeks after the start of the treatment. The progression-free survival ranged from a median of 5 months in a study using cisplatin/etoposide, to 11 months in a study with paclitaxel/carboplatin. The median survival was 11-15 months. The outpatient weekly paclitaxel/carboplatin regimen, with paclitaxel at a dose of 90 mg/m(2) and carboplatin at area under the curve 4, seems similarly effective and is better tolerated. Dose-dense weekly paclitaxel/carboplatin is an effective and well-tolerated therapy for platinum-sensitive, as well as platinum-resistant tumors. Responses to therapy are observed within 8 weeks in the majority of the patients. Whether a weekly regimen indeed is more effective than 3-weekly paclitaxel/carboplatin needs to be answered in a randomized study.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1048-891X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15 Suppl 3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
233-40
|
| pubmed:dateRevised |
2006-11-7
|
| pubmed:meshHeading |
pubmed-meshheading:16343238-Adult,
pubmed-meshheading:16343238-Aged,
pubmed-meshheading:16343238-Aged, 80 and over,
pubmed-meshheading:16343238-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16343238-Carboplatin,
pubmed-meshheading:16343238-Cisplatin,
pubmed-meshheading:16343238-Dose-Response Relationship, Drug,
pubmed-meshheading:16343238-Drug Administration Schedule,
pubmed-meshheading:16343238-Drug Resistance, Neoplasm,
pubmed-meshheading:16343238-Etoposide,
pubmed-meshheading:16343238-Female,
pubmed-meshheading:16343238-Gynecologic Surgical Procedures,
pubmed-meshheading:16343238-Humans,
pubmed-meshheading:16343238-Middle Aged,
pubmed-meshheading:16343238-Ovarian Neoplasms,
pubmed-meshheading:16343238-Paclitaxel,
pubmed-meshheading:16343238-Prognosis,
pubmed-meshheading:16343238-Survival Analysis,
pubmed-meshheading:16343238-Treatment Outcome
|
| pubmed:articleTitle |
What is the role of dose-dense therapy?
|
| pubmed:affiliation |
Department of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
|
| pubmed:publicationType |
Journal Article,
Review
|